Khalil Garada

Khalil Garada

Auto-generated profile, based on publicly available information

Khalil Garada

Faculty of Medicine, University of Debrecen, 4032, Egyetem Tér 1, Debrecen, Hungary

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ASAlrayyan Private school
Alrayyan Private school
KGKhalil Garada
Khalil Garada
RHReem Al Huneidi
Reem Al Huneidi
ZBZaid M.H. Baddar
Zaid M.H. Baddar
AZAyman A. Zarour
Ayman A. Zarour
KAKhalid Alrumaihi
Khalid Alrumaihi
Ataxia-telangiectasia mutated (ATM) kinase plays a pivotal role in the cellular response to DNA damage. Under normal conditions, ATM acts as a tumor suppressor by regulating pathways that lead to apoptosis and cell cycle arrest via effectors like p53, p21, CHK1, and CHK2. Paradoxically, in some cancers, ATM promotes tumor cell survival and metastasis, especially when aberrantly activated, linking it to therapy resistance and poor outcomes. Its involvement in both radiotherapy and chemotherapy has made ATM an attractive target for cancer treatment. Inhibitors such as KU-55933, KU-60019, and AZD1390 have shown the potential to sensitize cancer cells to radiotherapy by impairing DNA repair, thereby enhancing treatment efficacy. A key challenge remains the development of ATM inhibitors that can effectively cross the blood-brain barrier for use against brain tumors. Currently, none have gained approval from the FDA or EMA, but six candidates, AZD1390, AZD0156, ZN-B-2262, SYH2051, WSD0628 and M3541 are in clinical trials, often as adjuncts to radiotherapy or in combination with PARP inhibitors. Their safety and effectiveness, however, are still under investigation. This review synthesizes ATM's dual roles and the therapeutic promise of targeting ATM in cancer radiotherapy.

20 May 2026 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
ASAlrayyan Private school
Alrayyan Private school
KGKhalil Garada
Khalil Garada
AZAyman A. Zarour
Ayman A. Zarour
MEMai Elaarag
Mai Elaarag
AFAla’A Farhan
Ala’A Farhan
KAKhalid Alrumaihi
Khalid Alrumaihi
Despite advancements in breast cancer treatment, breast cancer is still among the major causes of cancer-related deaths worldwide, with most breast cancers being estrogen receptor positive (ER+). Selective estrogen receptor modulators (SERMs) have been the core drug class used in endocrine therapy for ER+ breast cancer through tissue-specific conformational changes to the estrogen receptor. The present study critically evaluates the pharmacologic development, thermodynamics, and clinical effectiveness of SERMs. We systematically analyze approved agents (e.g., tamoxifen, raloxifene, bazedoxifene), investigational drugs (e.g., endoxifen, lasofoxifene), and historically discontinued compounds to understand the structural basis of their clinical successes and failures. Furthermore, we explore the molecular drivers of SERM resistance, including ESR1 mutations, epigenetic reprogramming, and growth factor cross-talk. By highlighting the limitations of early-generation SERMs, such as paradoxical partial agonism, thromboembolic risks, and acquired resistance, we provide a rationale for the current paradigm shift toward Complete Estrogen Receptor Antagonists (CERANs) and oral Selective Estrogen Receptor Degraders (SERDs), offering critical insights into the future of precision endocrine oncology.

10 February 2026 in Drug Development Research
Verified
Journal Article
Closed access
ASAlrayyan Private school
Alrayyan Private school
MEMai Elaarag
Mai Elaarag
AZAyman A. Zarour
Ayman A. Zarour
KGKhalil Garada
Khalil Garada
SASally R. Al‐Zoubi
Sally R. Al‐Zoubi
KAKhalid Alrumaihi
Khalid Alrumaihi

1 January 2026 in Anesthesiology Research and Practice
Verified
Journal Article
Open access
PDF file
MMMarc Knezevic Maragh
Marc Knezevic Maragh
AGAlanna Pagan Garcia
Alanna Pagan Garcia
YOYuliia Oliinyk
Yuliia Oliinyk
JAJayottri Acharjee
Jayottri Acharjee
ABAlex Emmanuel Binoy
Alex Emmanuel Binoy
KRKhalé Reyes
Khalé Reyes
Awake craniotomy is a standard neurosurgical technique that enables real‐time assessment of brain functions during tumor resection, with high success rates. Although highly effective, the procedure is associated with hemodynamic disturbances, including blood pressure variability and impaired cerebral perfusion, compromising intraoperative safety. A focused literature search of PubMed, Embase, and Google Scholar was performed to identify relevant studies on intraoperative hemodynamic management during awake craniotomy. Findings were synthesized narratively to summarize current evidence, highlight emerging strategies, and identify knowledge gaps. Hypertension (8%–34%) was the most common disturbance, often triggered by painful surgical stimuli or emergence from sedation, with repeat craniotomy, impaired autoregulation, and glioma pathology as additional risk factors. Hypotension (10%–11%) was linked to perioperative stroke and mortality. Cerebral hypoperfusion contributed to poor outcomes, with stroke up to 23% and neurological morbidity in 68% of patients. Preventive strategies, such as scalp blocks, individualized blood pressure targets, and the use of dexmedetomidine and midazolam, improved intraoperative stability, while short‐acting agents, including esmolol and labetalol, were preferred for rapid control. Advanced monitoring modalities, including arterial lines, near‐infrared spectroscopy, and cerebral autoregulation indices, enhance safety and support accurate functional mapping. Hemodynamic instability during awake craniotomy influences outcomes. Current evidence supports multimodal prevention, tailored blood pressure control, and short‐acting pharmacological agents; practice variation and the lack of randomized trials limit standardization. Looking ahead, advanced monitoring and emerging AI systems may provide new opportunities to enhance cerebral protection and optimize patient safety. This review summarizes evidence on intraoperative hemodynamic control in awake craniotomy, emphasizing strategies that enable maximal safe resection while preserving neurological function.